Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12456810 | 1.00 | GSR (0.36) | GSRALDH1A1CA2 | |
| SCHEMBL12456825 | 0.92 | GSR (0.37) | GSRALDH1A1CA2 | |
| SCHEMBL12456826 | 0.89 | GSR (0.36) | GSRALDH1A1CA2 | |
| SCHEMBL12456812 | 0.89 | GSR (0.36) | GSRALDH1A1CA2 | |
| SCHEMBL12456808 | 0.89 | GSR (0.36) | GSRALDH1A1CA2 | |
| SCHEMBL14499700 | 0.83 | GSR (0.36) | GSRALDH1A1CA2 | |
| SCHEMBL12456814 | 0.80 | GSR (0.40) | GSRALDH1A1CA2 | |
| SCHEMBL14499676 | 0.78 | GSR (0.43) | GSRALDH1A1CA2 | |
| SCHEMBL14499695 | 0.78 | GSR (0.43) | GSRALDH1A1CA2 | |
| SCHEMBL27736502 | 0.78 | GSR (0.43) | GSRALDH1A1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133150-B2 | O-nitro compounds and pharmaceutical compositions including same | ORBITAL ATK, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20130309324-A1 | O-NITRO COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS INCLUDING SAME | RADIORX, INC., C/O INTERWEST VENTURE PARTNERS (US) | 2013-11-21 | — | — | US | disclosed |
| US-8530681-B2 | Pharmaceutical compositions of O-nitro compounds | ALLIANT TECHSYSTEMS INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-20120237615-A1 | PHARMACEUTICAL COMPOSITIONS OF O-NITRO COMPOUNDS | RADIORX, INC., C/O INTERWEST VENTURE PARTNERS (US) | 2012-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120237615-A1 | PHARMACEUTICAL COMPOSITIONS OF O-NITRO COMPOUNDS | NOS1, NOS2, NOS3 | GSR 155/4885ALDH1A1 1059/4885CA2 1445/4885 |
| US-20130309324-A1 | O-NITRO COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS INCLUDING SAME | NOS1, NOS2, NOS3 | GSR 241/4885ALDH1A1 957/4885CA2 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.